<DOC>
	<DOCNO>NCT02025413</DOCNO>
	<brief_summary>The primary objective preliminary lead-in study determine whether circulate tumor cell patient metastatic progressive castration-resistant prostate cancer metastatic progressive breast cancer capture use novel mesenchymal-marker base ferrofluid ( N-cadherin O-cadherin base ) . The primary objective comparative cohort ( second stage , prostate cancer ) compare non-detection rate circulate tumor cell standard novel method .</brief_summary>
	<brief_title>Isolation Circulating Tumor Cells Using Novel EMT-Based Capture Method</brief_title>
	<detailed_description />
	<mesh_term>Neoplastic Cells , Circulating</mesh_term>
	<criteria>Prostate cancer patient eligible inclusion study follow criterion apply : 1 . Histologically confirm diagnosis adenocarcinoma prostate . Small cell neuroendocrine tumor prostate also permit . 2 . Clinical radiographic evidence metastatic disease . 3 . Castrate level testosterone ( &lt; 50 ng/dl ) 4 . Evidence disease progression follow recent therapy evidence clinically treat physician either following : Two consecutive PSA level great PSA nadir achieve ADT , separate great one week Radiographic evidence disease progression define new bone scan lesion growth soft tissue/visceral metastasis &gt; 1 cm diameter ( 2 cm lymph node ) . 5 . Age &gt; 18 year . 6 . Ability understand willingness sign write informed consent document . Breast cancer patient eligible inclusion study follow inclusion criterion apply : 1 . Histologically confirm diagnosis invasive breast cancer . 2 . Clinical radiographic evidence metastatic disease . 3 . Evidence disease progression current follow recent therapy , determine either clinically treat physician radiographic evidence define new bone scan lesion soft tissue/visceral metastasis &gt; 1 cm diameter ( 2 cm lymph node ) . 4 . Age &gt; 18 year . 5 . Ability understand willingness sign write informed consent document . A patient eligible inclusion study follow criterion apply : 1 . History intercurrent past medical psychiatric illness would make participation blood draw protocol difficult feasible discretion principal investigator coinvestigator ( ) . 2 . Treatment anthracycline mitoxantrone within 1 week CTC collection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>